Home » Aveo Pharmaceuticals Starts Exploratory Biomarker Trial Enrollment
Aveo Pharmaceuticals Starts Exploratory Biomarker Trial Enrollment
Cambridge-based AVEO Pharmaceuticals Inc. said it has started enrolling patients in a Phase II exploratory biological marker study of tivozanib, its lead treatment for renal cell carcinoma.
Mass High Tech
Mass High Tech
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May